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Objectives: Comorbidmajor depression is associatedwith reduced quality of life and greater use of healthcare re-
sources. A recent randomised trial (SMaRT, SymptomManagement Research Trials, Oncology-2) found that a col-
laborative care treatment programme (Depression Care for People with Cancer, DCPC) was highly effective in
treating depression in patients with cancer. This study aims to estimate the cost-effectiveness of DCPC compared
with usual care from a health service perspective.
Methods: Costs were estimated using UK national unit cost estimates and health outcomes measured using
quality-adjusted life-years (QALYs). Incremental cost-effectiveness of DCPC comparedwith usual carewas calcu-
lated and scenario analyses performed to test alternative assumptions on costs andmissing data. Uncertaintywas
characterised using cost-effectiveness acceptability curves. The probability of DCPC being cost-effective was de-
termined using the UK National Institute for Health and Care Excellence's (NICE) cost-effectiveness threshold
range of £20,000 to £30,000 per QALY gained.
Results:DCPC cost on average £631more than usual care per patient, and resulted in amean gain of 0.066 QALYs,
yielding an incremental cost-effectiveness ratio of £9549 per QALY. The probability of DCPC being cost-effective
was 0.9 or greater at cost-effectiveness thresholds above £20,000 per QALY for the base case and scenario
analyses.
Conclusions: Comparedwith usual care, DCPC is likely to be cost-effective at the current thresholds used by NICE.
This study adds to the weight of evidence that collaborative care treatment models are cost-effective for
depression, and provides new evidence regarding their use in specialist medical settings.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Major depression is a leading cause of disabilityworldwide [1,2]. It is
also an important cause of work place absenteeism and reduced pro-
ductivity [3]. Major depression that is comorbid with a chronic disease
has a particularly large effect: it is associated with substantial decre-
ments in health and a signiﬁcant increase in patients' use of health
care resources [4–6]. Despite its importance, the treatment of major
depression is often suboptimal [7].
The collaborative caremodelwasdevelopedwith the aimof improv-
ing the management of depression in primary care [8]. The model em-
phasises systematic treatment delivery and efﬁcient use of specialist
skills to deliver evidence-based treatment to a large number of patients.
Many trials have found the collaborative care model to be an effective
and cost-effective way of treating depression in primary care, and the
model is now being developed further to treat depression comorbid
with chronic disease [9–13].
Cancer is becoming a chronic disease for a rapidly increasingnumber
of people [14]. Major depression affects approximately 10% of patients
with cancer but, despite the signiﬁcant health care resources devoted
to cancer care, few of these patients receive treatment for depression
[15]. ‘Depression Care for People with Cancer’ (DCPC) is a development
of the collaborative care model for patients with cancer and comorbid
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major depression. It is a multicomponent, manualised treatment
programme that integrates specialist depression management with
both cancer treatment and primary care [16]. The ﬁndings of SMaRT
(Symptom Management Research Trials) Oncology-2, a 500 patient
multicentre randomised controlled trial which found that DCPC was
highly effective when compared with usual care, have recently been
published [17]. However, its implementation in clinical practice also
requires evidence about its cost-effectiveness.
This paper reports on a cost-effectiveness analysis of DCPC com-
pared with usual care from a health service perspective using data
from SMaRT Oncology-2.
Methods
Study design and participants
SMaRT Oncology-2 was a two-arm, parallel group, multicentre
randomised controlled trial in three cancer centres in Scotland, UK
(Glasgow, Edinburgh and Dundee) and their associated clinics [17].
The trial included 500 adults (aged ≥ 18 years) with a diagnosis of can-
cer, a good cancer prognosis (predicted survival ≥ 12months estimated
by their cancer specialist) and major depression (Diagnostic and Statis-
ticalManual ofMental Disorders, 4th Edition [DSM-IV] criteria using the
inclusive approach to diagnosis) of at least four weeks' duration
[18–20]. Patients were excluded if they were unable to participate in
DCPC (those with substantial cognitive or communication difﬁculties,
or who could not attend regular sessions), or if DCPCwas inappropriate
to their needs (thosewith continuous depression for ≥2 years, a psychi-
atric or medical condition requiring alternative treatment, known cere-
bral metastases, or those already regularly seeing a mental health
specialist). Written consent was obtained from all participants. Ethical
approval was given by the ‘Scotland A’ Research Ethics Committee
(08/MRE00/23).
Interventions
DCPC
DCPC has been described in detail elsewhere [16]. In summary, it is
an intensive, manualised, collaborative care-based multicomponent
treatment programme speciﬁcally designed to be integrated with the
patient's cancer treatment. DCPC is systematically delivered by a team
that comprises specially trained cancer nurses and supervising psychia-
trists working in collaboration with the patient's oncology team and
primary care physician. The nurses establish a therapeutic relationship
with the patients, provide information about depression and its
treatment, deliver brief evidence-based psychological interventions
(problem-solving therapy and behavioural activation) and monitor
patients' progress. The psychiatrists supervise treatment, aiming to
achieve andmaintain treatment targets, advise primary care physicians
about prescribing antidepressants, and provide direct consultations to
patients who are not improving. The initial treatment phase comprises
a maximum of ten sessions with the nurse (at the cancer or primary
care clinic, or if necessary by telephone) over a four-month period.
After this initial treatment period, patients' progress is monitored
monthly by telephone (through an automated system supplemented
by nurse calls) for a further eight months; additional sessions with the
nurse are provided for patients not meeting treatment targets.
Usual care
The participant's primary care physician and oncologist were in-
formed about the major depression diagnosis and asked to treat their
patients as they normallywould. The patientwas encouraged to consult
their primary care physician to obtain treatment.
Resource use and costs
The team delivering DCPC recorded: the duration, setting (hospital,
home) and professionals (nurse, psychiatrist) present at each treatment
session; the duration of all telephone calls to patients and primary care
physicians; and related administrative time and average time per pa-
tient in supervision sessions. Data were collected on the following
healthcare resource use by participant report (using questionnaires ad-
ministered by post or read out to the patient by telephone interviewers)
supplemented by case note review (by clinical researchers to determine
the type of appointment, hospital stay or treatment received): inpatient
hospital and hospice stays; accident and emergency (A&E) attendances;
outpatient appointments for cancer treatment; outpatient appoint-
ments for psychological treatment; attendance at NHS-funded day hos-
pices; primary care consultations; relevant prescribed medications
(antidepressants, analgesics and anticancer medication). Researchers
involved in data collection were blind to treatment allocation.
Total healthcare costs were estimated by multiplying the cost of
each unit of resource, using UK national unit cost estimates (pounds
sterling at 2010–11 prices), by the amount used [21]. The full cost of
training the nurses who delivered DCPC in SMaRT Oncology-2 does
not reﬂect the cost of this training in a real-world setting because nurses
will retain the skills acquired for longer than the duration of the trial.
Therefore, a more appropriate estimate of this capital cost (as training
costs per patient treated with DCPC) was derived by assuming a ﬁve-
year tenure for each DCPC nurse (with no requirement for re-
training), an annual ﬂow of 60 patients per nurse and an annual
discount rate of 3.5%. Discounting was not applied to any other costs
or outcomes because the time horizon of the study was less than one
year.
Outcomes
Quality-adjusted life years (QALYs) were estimated based on
patients' responses to the EQ-5D-3L health-related quality of life
(HRQoL) questionnaire at baseline and at 12, 24, 36 and 48 weeks
post-randomisation [22]. The EQ-5D-3L asks patients to rate the sever-
ity of their problems (no problem, moderate problems or severe
problems) in the following domains: mobility, self-care, usual activity,
pain/discomfort and anxiety/depression. These ratings deﬁne health
states which have been assigned scores using preferences measured in
a representative sample of the UK population [23,24]. The EQ-5D scores
at each time-point were used to estimate QALYs using the area under
the curve method, which multiplies HRQoL weights by time [25].
Mean differences in QALYs were estimated per treatment group using
linear regression adjusting for baseline EQ-5D-3L score [26].
Analysis
A cost-effectiveness analysis was conducted from a healthcare per-
spective using the intention to treat principle with a time horizon of
48 weeks. The mean difference in healthcare costs incurred and QALYs
accrued between treatment groups were estimated using ordinary
least squares regression analyses, with robust standard errors to guard
against heteroscedasticity [27]. The mean difference in QALYs was ad-
justed by baseline EQ-5D-3L score to address any baseline imbalance
between groups. No other baseline covariate adjustment was per-
formed in the QALY or cost regression analyses for the purpose of this
paper. The adjustment of differences in costs and QALYs based on
other baseline characteristics (gender, cancer centre, and, cancer type)
did not affect the cost-effectiveness results, and regression coefﬁcients
were non-signiﬁcant at a 95% conﬁdence level. These results are, there-
fore, not shown, but are available on request.
Multiple imputation methods were used with chained equations
and predictive mean matching over 10 imputations to estimate cost
and EQ-5D-3L data items when these were missing. The following
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independent covariates were speciﬁed for the imputation model: gen-
der, age (≤50, 51–60, N60), baseline EQ-5D-3L score, cancer centre
(Glasgow, Edinburgh, Dundee), cancer type (breast, genito-urinary,
gynaecological, other).
In the base-case (primary) analysis the additional cost per QALY
gained (incremental cost-effectiveness ratio, ICER) of DCPC was calcu-
lated compared with usual care based on depression-related healthcare
costs (DCPC, antidepressant medication, psychological treatments).
This ICER was compared with the cost-effectiveness threshold range
of £20,000 to £30,000 per QALY gained (the threshold range adopted
by the UK National Institute for Health and Care Excellence [NICE])
[28]. Probabilistic sensitivity analysis was used to estimate decision un-
certainty; that is, the probability that the joint uncertainty in costs and
QALYs would result in DCPC not being cost-effective at a given cost-
effectiveness threshold. These probabilities were presented as cost-
effectiveness acceptability curves (CEACs). The analysis was performed
by simulating random draws of incremental mean costs and QALYs
(n = 1000) from a multivariate normal distribution and estimating
the proportion of those draws that corresponded to a cost-effective
use of resources at cost-effectiveness threshold values ranging from £0
to £50,000 per additional QALY [29].
Three scenario analyses were conducted to assess the robustness of
the ﬁndings to alternative assumptions regarding costs and missing
data. In principle, only costs that are likely to differ as a result of patients
receiving DCPC (rather than usual care) should be included in the analy-
sis. However, the conservative assumption used in the base-case analysis
that only depression-related costs would be affected may be incorrect as
it is plausible that DCPC could affect the use of other healthcare resources.
In scenario one, the costs associated with inpatient stays, A&E at-
tendances, outpatient appointments, attendance at day hospices and
primary care consultations were included, as well as the depression-
related healthcare costs used in the base-case analysis. In scenario
two, the costs of all resource use collected in the trial were included
(by further including the costs associated with analgesics and cancer
drugs). In scenario three, only those participants for whom complete
data were available were included (using only depression-related
healthcare costs).
All analyses were conducted using STATA/SE version 12.0 and
Microsoft Excel 2010.
Results
Sample characteristics
Of the 500 patients recruited to the trial 253 were allocated to DCPC
and 247 to usual care. Participants' characteristics at baseline did not
differ between the two groups, except for a slightly longer duration of
current depressive episode in the DCPC group. The extent of missing
HRQoL and cost data was similar between treatment arms. Further de-
tails of the sample have been reported previously [17].
Resource use and costs
The healthcare resources used over the 48week follow-up period by
trial participants for whom data were available and also the unit costs
associated with each type of resource use are shown in Table 1. Re-
source use was highly variable between individuals, as evidenced by
the large standard deviations, but was similar on average between pa-
tients allocated to DCPC and usual care, respectively, with the exception
ofmedication use. The proportion of participants prescribed antidepres-
sant medication was higher in those allocated to DCPC than those
randomised to usual care (80.4% vs. 59.5%), while the proportion pre-
scribed analgesics was lower (58.67% vs. 67.57%). The amount of miss-
ing data was similar between treatment arms for all categories of
resource use.
The estimated mean costs of resource use based on imputation of
missing data are shown in Table 2. Overall, mean total costs were higher
for the DCPC group than for the usual care group (£3463.69 vs. £2924.92
per patient), but the differences in most categories of costs were
small. Inpatient stays represented the largest share of healthcare
expenditure, comprising over 30% of total costs for both groups. The
mean cost of delivering DCPC was £642.13 per patient (representing
approximately 19% of the mean total costs incurred by participants
allocated to DCPC).
Table 1
Healthcare resources used by SMaRT Oncology-2 trial participants and their unit costs over 48 weeks.
Resource Unit costs DCPC (n = 253)a Usual care (n = 247)a
Unit Unit cost or
range (£)
Source of unit
costs
Mean
(SD)
Median
(IQR)
Used by (%) Data
completeness
(%)
Mean (SD) Median
(IQR)
Used by (%) Data
completeness
(%)
DCPCb Contact 44.00–142.50 PSSRU 11.89 (5.35) 13.00
(9–16)
96.0 100.0 – – – –
Psychological
treatment
Visits 14.81–68.50 PSSRU 0.27 (1.36) 0 (0–0) 12.6 84.6 1.00
(2.83)
0 (0–0) 18.1 87.4
Antidepressant
medication
Item Various BNF – – 80.4 88.9 – – 59.5 89.9
Inpatient stays Length of
stay
Various NHS reference
costs
2.2(6.44) 0 (0–1) 25.1 86.6 3.23
(10.49)
0 (0–1) 27.4 88.7
A&E
attendances
Visits 117.47 NHS reference
costs
0.44(0.79) 0 (0–1) 29.6 87.0 0.32
(0.70)
0 (0–0) 22.2 87.4
GP
appointments
Visits 25.00–82.00 PSSRU 10.14 (7.99) 9 (4–14) 93.4 84.2 9.79
(7.66)
9.00
(5–12)
95.8 85.8
Cancer-related
appointments
Visits 11.11–118.79 PSSRU NHS
reference
costs
11.22
(19.06)
5 (2–12) 88.9 78.3 10.36
(15.08)
6 (3–11) 91.1 77.3
Day centres Visits 28.00 PSS–EX 2.01(8.89) 0 (0–0) 14.2 81.0 2.72
(9.50)
0 (0–0) 17.6 80.6
Cancer
medication
Item Various BNF – – 45.1 88.5 – – 50.4 89.9
Analgesic
medication
Item Various BNF – – 58.7 88.9 – – 67.6 89.9
DCPC, Depression Care for People with Cancer; A&E, accident and emergency; BNF, British National Formulary; IQR, interquartile range; PSS-EX, Personal Social Services: Expenditure and
Unit Costs; PSSRU, Personal Social Services Research Unit, Unit Costs of Health and Social Care; SD, standard deviation.
a Results based on the available case data set, as multiple imputation was only performed for costs and not for resource use.
b Includes face to face and telephone sessions.
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Outcomes
Table 3 shows the health outcomes at each time point. On average,
there was an improvement in HRQoL from baseline until 36 weeks in
the DCPC group, but only until 24 weeks for the usual care group. The
mean total QALYs accrued during the 48-week trial period were higher
for the DCPC group than for the usual care group (0.4913 vs. 0.4413 per
patient), (these estimates do not account for differences in baseline
HRQoL).
Cost effectiveness analysis
Base-case analysis
In the base-case analysis DCPC generated 0.066 more QALYs than
usual care at an additional cost of £631.30 per patient, yielding an
ICER of £9549 per additional QALY (Table 4). The probability of DCPS
being cost-effective at the NICE cost-effectiveness threshold range is
depicted in Fig. 1. It suggests that, for thresholds above approximately
£10,000 per QALY, DCPC ismore likely to be the cost-effective treatment
than usual care with a probability greater than 0.5. The probability of
DCPC being cost-effective when compared with usual care is situated
between 0.98 and 0.99 for NICE's commonly adopted range of thresh-
olds (£20,000 to £30,000 per additional QALY).
Scenario analyses
The results of the scenario analyses are shown in Table 4. In scenar-
ios one (all collected costs except cancer and analgesic medication) and
two (all costs) the ﬁndings were consistent with those of the base-case
analysis. However, the mean cost difference between DCPC and usual
care was smaller in these two scenarios, with a reduction of the corre-
sponding ICERs (£8851.70 and £8149 per additional QALY for scenarios
one and two, respectively, compared with the base-case estimate of
£9549). Uncertainty was increased by the greater variability of costs
(as shown by wider 95% conﬁdence intervals that include zero), and
the probability of DCPC being cost-effective decreased but remained
higher than 0.9 for the NICE threshold range. The ﬁndings of scenario
three (based on complete case data) were also consistent with the ﬁnd-
ings based on imputed data. The mean incremental costs of DCPC com-
pared with usual care were higher than in the base-case analysis (£648
vs. £631 per patient), and the mean incremental QALYs were smaller
(0.062 vs.0.066 per patient), resulting in an ICER of £10,400 per addi-
tional QALY. The probabilities of DCPC being cost-effectivewere smaller
than in the base case analysis, but remained 0.9 or greater for the con-
sidered thresholds. The increased uncertainty in this analysis appears
to result from greater variability of both costs and QALYs estimated
from the smaller complete case data set (n = 309).
Discussion
DCPC is likely to be cost-effective when compared with usual care
for major depression in patients with cancer. This ﬁnding was robust
to uncertainty and to the variation of assumptions regarding the types
of healthcare costs included and the nature of missing data.
Cost-effectiveness thresholds are used by healthcare systems with
limited budgets because, in principle, any new costs incurred by
adopting more expensive interventions lead to a reduction in spending
and, therefore, health forgone by other types of patient (opportunity
costs). The ICER in this cost-effectiveness analysis was £9549 per addi-
tional QALY (with a range of £7004 to £10,400 in the different scenario
analyses) which is substantially less than the cost-effectiveness thresh-
olds of £20,000 to £30,000 per QALY gained currently used by NICE in
the UK [28]. To inform judgements about the NICE cost-effectiveness
threshold, recent research has used routine data to provide the ﬁrst em-
pirical estimate of the health forgone when the NHS incurs additional
costs [30]. This suggests that the threshold should be nearer £13,000
per QALY gained. The estimates of the ICER for DCPC in this paper sug-
gest that it remains cost-effective, even at this lower threshold.
We only included depression-related health care use in the base-
case analysis to minimise uncertainty and imprecision. However, the
scenario analyses, which include other healthcare costs, suggest that
Table 2
Unadjusted total costs in pounds sterling of resource use by SMaRT Oncology-2 trial participants (2010–11 prices) over 48 weeks from imputed data sets.
Costs DCPC (n = 253) Usual care (n = 247)
Mean (SE) 95% CI % total costs Mean (SE) 95% CI % total costs
DCPCa 642.13 (16.39) 609.85–674.42 18.5 – – –
Psychological treatment 7.67 (2.38) 2.99–12.35 0.2 27.28 (4.86) 17.71–36.86 0.9
Antidepressant medication 28.63 (2.16) 24.37–32.89 0.83 19.85 (2.60) 14.73–24.96 0.7
Inpatient stays 1,059.87 (192.45) 680.33–1,439.41 30.6 1,093.57 (231.08) 638.01–1549.14 37.4
A&E attendances 50.56 (6.00) 38.74–62.39 1.5 41.57 (5.45) 30.82–52.31 1.4
GP appointments 367.97 (22.94) 322.75–413.18 10.6 341.94 (19.76) 302.98–380.90 11.7
Cancer-related appointments 542.97 (48.90) 446.59–639.34 15.7 582.45 (43.85) 496.03–668.88 19.9
Day centres 27.95 (7.30) 13.57–42.32 0.8 35.89 (7.36) 21.39–50.39 1.2
Cancer medication 588.30 (171.49) 250.34–926.27 17.0 543.72 (144.17) 259.73–827.71 18.6
Analgesic medication 147.64 (40.18) 68.50–226.77 4.3 238.65 (70.25) 100.28–377.03 8.2
Total 3463.69 (308.40) 2855.74–4071.65 100.0 2924.92 (312.93) 2308.35–3541.52 100.0
a Includes face to face and telephone sessions. A&E, accident and emergency; CI, conﬁdence interval; SE, standard error.
Table 3
Unadjusted EQ-5D summary scores and QALYs over 48 weeks from imputed data sets.
Outcome EQ-5D scores DCPC (n = 253) Usual care (n = 247)
Mean (SE) 95% CI Data completenessa (%) Mean (SE) 95% CI Data completenessa (%)
Baseline 0.4492 (0.0196) 0.4107–0.4870 100.0 0.4816 (0.0188) 0.4445–0.5186 100.0
12 weeks 0.5346 (0.0205) 0.4941–0.5751 93.7 0.5016 (0.0196) 0.4630–0.5402 98.4
24 weeks 0.5543 (0.0210) 0.5130–0.5966 93.7 0.4830 (0.0208) 0.4420–0.5240 94.7
36 weeks 0.5566 (0.0212) 0.5148–0.5984 93.3 0.4603 (0.0213) 0.4183–0.5023 96.4
48 weeks 0.5179 (0.0231) 0.4723–0.5635 94.5 0.4534 (0.0225) 0.4092–0.4977 95.1
QALYs 0.4913 (0.0160) 0.4599–0.5228 88.9 0.4413 (0.0155) 0.4108–0.4719 89.9
a In available case data set. CI, conﬁdence interval; SE, standard error.
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DCPC may reduce costs (particularly those not directly related to de-
pression treatment) as well having signiﬁcant beneﬁcial effects on
HRQoL. The incremental costs of DCPC compared with usual care
when non depression-related costs are included (£585 and £539 in sce-
narios 1 and 2, respectively) are always less than the cost of delivering
DCPC (£642). This ﬁnding should be interpreted cautiously given the
relatively small sample size. However it is consistent with the evalua-
tion of DCPC's clinical effectiveness in which patients who received
DCPC were found to have much greater improvements not only in de-
pression but also in physical symptoms such as pain [17].
This study has several limitations: First, we relied on self-reported
information to obtain data on service use, and supplemented these
with data from case note review. Whilst self-report may have led to
data inaccuracies, there are no practical alternatives. The accuracy of
the cost estimates was also enhanced by the direct recording of all
DCPC treatment activities. Second, the analysis is based on the data col-
lected in a single randomised controlled trial and does not, therefore, in-
clude all sources of evidence. However, the ﬁndings are consistent with
those of a previous cost-effectiveness analysis based on data from an
earlier efﬁcacy trial of DCPC (n = 200) [31]. A decision analytic model
that evaluated the cost-effectiveness of DCPC combinedwith systematic
depression screening for patients attending specialist cancer clinics also
suggested that DCPC was likely to be cost-effective (32). Third, the trial
was conducted in the one particular health-care system (the UK NHS).
However the organisation of cancer care is similar to that inmost devel-
oped countries with both primary and specialist health-care systems.
Fourth, the time horizon of the cost-effectiveness analysis is limited by
the duration of the trial (48 weeks) and as costs of the intervention
occur early, it is possible that some additional beneﬁt (and, subject to
the caveat above, cost savings) would continue beyond 48 weeks.
Consequently we may have under-estimated the long-term cost-
effectiveness of DCPC.
Published reviews of the cost-effectiveness of collaborative care in-
terventions (11,33,34) have, of necessity, focused on studies conducted
in primary care settings. This analysis adds to the weight of evidence
that collaborative care models are a cost-effective way to deliver de-
pression care and provides new evidence regarding their use in special-
ist medical settings and for the treatment of depression in cancer
patients speciﬁcally.
In summary, the collaborative care based DCPC treatment pro-
gramme is not only an effective treatment for major depression in pa-
tients with cancer but also likely to be a cost-effective one. Whist local
health care commissioners will need to assess the generalisability of
the results of SMaRT Oncology-2 to their own populations, and the ap-
propriate cost-effectiveness threshold in their setting. The results pre-
sented here suggest a strong case for the widespread implementation
of DCPC into cancer care.
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